Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Reports from L.M. Peterson et al highlight recent research in breast cancer
May 1st, 2008
According to recent research from the United States, "The PET compound F-18-fluoroestradiol (F-18-FES) has been developed and tested as an agent for the imaging of estrogen receptor (ER) expression in vivo. F-18-FES uptake has been shown to correlate with ER expression assayed in vitro by radioligand binding; however, immunohistochemistry (IHC) rather than radioligand binding is used most often to measure ER expression in clinical practice." "We therefore compared F-18-FES uptake with ER expression assayed in vitro by IHC with both qualitative and semiquantitative measures. Seventeen patients with primary or metastatic breast cancer were studied with dynamic F-18-FES...
Source: Women's Health Weekly (2008-05-01)
|
